A recent study reveals that individuals who discontinue new slimming jabs like semaglutide or tirzepatide can put back on shed pounds far faster than those who stop conventional lifestyle regimens.
Findings released in a prominent health publication shows that while overweight people often shed about a fifth of their total mass while on the medication, the mass comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals using such medications need to be aware of the risk of quick weight regain when the therapy ends," stated expert Dr. Susan Jebb.
Such speed of regain suggests a return to starting weight within about one and a half years.
Analyzing Therapies
The research, which examined 37 of studies involving over 9,000 of patients, contrasted the effects of GLP-1 agonists with conventional dieting.
The team point out that people who lose weight through lifestyle changes alone typically see a less rapid weight regain—around 0.1 kg a month—post-intervention.
Explaining the Quick Rebound
Experts suggest the way of the drugs is key to understanding the accelerated rebound.
These medications mimic a body's own chemical called GLP-1, which moderates feelings of fullness.
"Sustained high doses of GLP-1 concentrations far above than normal might result in the system to produce less of its own natural GLP-1, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication means hunger is uncontrolled, making overeating a significant risk."
A Chronic Disease?
Health authorities suggest the jabs for people with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
Many experts contend that, considering the significant potential of weight regain, the treatment is often life-long.
This perspective is supported by pharmaceutical companies, who note that the results "highlight the persistent character of excess weight," akin to managing diseases like hypertension.
Patient Experiences
Individuals who have come off the jabs report a intense return of hunger.
"It felt as if a trigger that goes on and you're instantly ravenous," described an individual.
This difficulty is worsened if patients have not adopted lasting dietary or behavioural changes during therapy.
Significant Adoption
Recent estimates show that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow.
- Adoption is more common among females compared to men.
- The middle-aged demographic shows the greatest usage rates.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, researchers caution that while the jabs are effective agents for weight loss, they are not a magic cure and lasting health benefits relies on combined behavioural changes.
